PMA device
Aspiresr Generator -Model 106
LivaNova USA, Inc. · Stimulator, Autonomic Nerve, Implanted (Depression) (MUZ, Class III) · First FDA decision Dec 18, 2015, newest Dec 18, 2015DepressionEpilepsy
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
1
Naming "Aspiresr"
MAUDE reports
4
Brand "Aspiresr", since 2015
PubMed studies
19
Mentioning "Aspiresr"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Aspiresr Generator -Model 106
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ASPIRESR GENERATOR -MODEL 106PMA supplement
P970003-S182 · Decided Dec 18, 2015 · 170 days after receipt · Normal 180 Day Track
Device type: Stimulator, autonomic nerve, implanted (depression) (MUZ) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Phrenic Nerve StimulatorNational determinationOn the books160.19Updated Jun 12, 2020
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Aspiresr", any status and sponsor, newest update first.
Cyberonics, Inc.Public (LIVN)
NCT01325623 · 31 participants · Start Mar 2011 · Primary completion Jul 2013
Device: Model 106 VNS Therapy System · For: Epilepsy
Sites: Anderlecht, Belgium; Brussels, Belgium; Ghent, Belgium · 14 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Aspiresr", and for the whole product code for context.
This brand
4 reports: 3 malfunction, 1 injury, 0 death
Whole product code MUZ
952 reports: 394 malfunction, 514 injury, 44 death
Newest reports for this brand
1644487-2025-10959 · Received Dec 15, 2025 · Event dated Nov 12, 2025
Device type: Stimulator, Autonomic Nerve, Implanted For Epilepsy (LYJ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Medical device site infection
- VNS THERAPY® ASPIRESR® MODEL 106 GENERATORMalfunction
23435860 · Received Oct 31, 2025 · Event dated Oct 18, 2025
Device type: Stimulator, Autonomic Nerve, Implanted For Epilepsy (LYJ)
Device problem as coded: Computer Software Problem; Connection Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- VNS THERAPY ASPIRESR MODEL 106 GENERATORMalfunction
16643971 · Received Mar 30, 2023 · Event dated Feb 7, 2023
Device type: Stimulator, Autonomic Nerve, Implanted For Epilepsy (LYJ)
Device problem as coded: Patient-Device Incompatibility
Patient problem as coded: Failure of Implant
1 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1067-2025 · Started Jan 3, 2025 · Posted by FDA Jan 30, 2025
Reason given: Their is a potential that implanted pulse generators may stop delivering therapy due to an internal component issue.
Cause as FDA categorized it: Device Design · Device type: Stimulator, Autonomic Nerve, Implanted For Epilepsy (LYJ)
Z-1068-2025 · Started Jan 3, 2025 · Posted by FDA Jan 30, 2025
Reason given: Their is a potential that implanted pulse generators may stop delivering therapy due to an internal component issue.
Cause as FDA categorized it: Device Design · Device type: Stimulator, Autonomic Nerve, Implanted For Epilepsy (LYJ)
- SenTiva, REF: 1000; SenTiva Duo, REF: 1000-D; Generators Part of the VNS Therapy System. Used for Vagus Nerve Stimulation (VNS).Open, Classified
Z-1072-2025 · Started Dec 12, 2024 · Posted by FDA Jan 31, 2025
Reason given: Vagus nerve stimulator generators may stop delivering stimulation due to an internal, mechanically activated component that may become stuck in a closed position, which may result in patients returning to baseline seizure frequency or depressive symptoms and in the longer term, patients may be required to undergo...
Cause as FDA categorized it: Device Design · Device type: Stimulator, Autonomic Nerve, Implanted For Epilepsy (LYJ)
27 more recall records with a free account
Published research
The most relevant PubMed records for "Aspiresr"[tiab]. The summary above synthesizes these.
- Clinical outcomes of closed-loop vagal nerve stimulation in patients with refractory epilepsy.
Tzadok M, Harush A, Nissenkorn A, et al. · Seizure · 2019
- Evaluating vagus nerve stimulation treatment with heart rate monitoring in pediatric patients with intractable epilepsy.
Santhumayor B, Karkare S, Kothare S, et al. · Childs Nerv Syst · 2022Research Support, Non-U.S. Gov't
- A 3-year-old child with multi-drug resistant epilepsy responding to pharmacological and nonpharmacological treatments.
Coskun Y, Yildirim C · Int J Neurosci · 2023Case Reports
- Additional seizure reduction by replacement with Vagus Nerve Stimulation Model 106 (AspireSR).
Kawaji H, Yamamoto T, Fujimoto A, et al. · Neurosci Lett · 2020
- Autostimulation in Vagus Nerve Stimulator Treatment: Modulating Neuromodulation.
Kulju T, Haapasalo J, Rainesalo S, et al. · Neuromodulation · 2019
- Responsive brain stimulation in epilepsy.
Hartshorn A, Jobst B · Ther Adv Chronic Dis · 2018Review
- Recent advances in devices for vagus nerve stimulation.
Mertens A, Raedt R, Gadeyne S, et al. · Expert Rev Med Devices · 2018Review
- Seizure improvement following vagus nerve stimulator (VNS) battery change with cardiac-based seizure detection automatic stimulation (AutoStim): early experience in a regional paediatric unit.
Lo WB, Chevill B, Philip S, et al. · Childs Nerv Syst · 2021Observational Study
- Early experiences with tachycardia-triggered vagus nerve stimulation using the AspireSR stimulator.
El Tahry R, Hirsch M, Van Rijckevorsel K, et al. · Epileptic Disord · 2016Case Reports
- Clinical outcomes of VNS therapy with AspireSR® (including cardiac-based seizure detection) at a large complex epilepsy and surgery centre.
Hamilton P, Soryal I, Dhahri P, et al. · Seizure · 2018Comparative Study
- Adverse Events and Complications Associated With Vagal Nerve Stimulation: An Analysis of the Manufacturer And User Facility Device Experience Database.
Lim YG, Ker JRX, Tan YL, et al. · Neuromodulation · 2024Review
- Automatic Vagus Nerve Stimulation Triggered by Ictal Tachycardia: Clinical Outcomes and Device Performance--The U.S. E-37 Trial.
Fisher RS, Afra P, Macken M, et al. · Neuromodulation · 2016Clinical Trial, Multicenter Study
Other devices of this type
Also filed under product code MUZ.
- Vns Therapy SystemLivaNova USA, Inc. · PMA 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.